Zika Vaccine Trials Could Test Multiple Candidates Vs. Common Control Group
FDA and NIH officials propose three strategies for clinical trials, saying it will be challenging to identify the most promising candidates; Sanofi and Walter Reed researchers note challenges in vaccine development, including manufacturing scale up.
You may also be interested in...
Chief Scientist At US FDA Is Hinton As Borio Moves To White House
Luciana Borio is detailed to National Security Council; FDA promotes Denise Hinton to acting chief scientist.
Pandemic Vaccines Probably Can’t Use Accelerated Approval – US FDA Chief Scientist
That’s not because the agency doesn’t want to get products cleared as fast as possible, Luciana Borio says; it’s because the pathway remains elusive for many pandemic treatments in the absence of surrogates due to largely undeveloped science.
Takeda In Hot Pursuit Of Zika Vaccine With $312m US Contract
Takeda is officially in the ballgame, joining the ranks of other firms like Sanofi Pasteur and GlaxoSmithKline, to find a vaccine against the Zika virus after snagging a US government R&D contract worth up to $312m.